Clinical trial · Interventional
Impact of Duffy-null Associated Neutropenia on Chemotherapy Dosing
A Prospective Study of Duffy-null Associated Absolute Neutropenia and Its Impact on Chemotherapy Dosing
NCT07743086CI-TRIAL-00124481not yet recruitingPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to: * In Phase 1 (observational) to develop an algorithm for treatment of Duffy-null positive patients for chemotherapy dosing * In Phase 2 (interventional), use the algorithm created in phase 1 to adjust chemotherapy dosing for Duffy-null patients
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumor Cancer | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Standard of Care chemotherapy Following an Algorithm | Drug | — | UNRESOLVED |
| Standard of Care chemotherapy following CTCAE criteria | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Duffy-null phenotype positive
- description
- In phase 2, Patients with a positive Duffy-null blood test plus standard of care chemotherapy with dose adjustment according to an algorithm created in phase 1 of this study.
- interventionNames
- Drug: Standard of Care chemotherapy Following an Algorithm
- type
- ACTIVE_COMPARATOR
- label
- Non-Duffy-null
- description
- In phase 2, patients with a negative Duffy-null blood test plus standard of care chemotherapy. Delays/modifications based on standard CTCAE (Common Terminology Criteria for Adverse Events) grading.
- interventionNames
- Drug: Standard of Care chemotherapy following CTCAE criteria
Primary outcomes (2)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Participant must self-identify as being of Middle Eastern or African descent. * Participant must be diagnosed with histologically or cytologically confirmed solid organ cancer and be treatment naive. * Melanoma is allowed; sarcoma is not eligible. * Secondary malignancies are allowed. * Participants who have received only surgery alone as treatment are eligible * Participant must be between the ages of 18-80. * Participant or their legally authorized representative (LAR) must be able to understand a written informed consent document and be willing to sign it. Exclusion Criteria: * Participants with active and uncontrolled bacterial, viral, or fungal infection requiring IV antibiotics. • Participants may be eligible for the study if the infection is deemed to be under control per investigator's discretion. * Participants who have ever received cytotoxic chemotherapy. • Those who have already started a chemotherapy regimen with moderate likelihood of developing neutropenia will be considered for enrollment at the principal investigator's discretion. * Participants who are receiving concurrent chemo-radiation treatment. * Participants who are taking any other investigational drugs. * Participants who are pregnant or breastfeeding. * Participants that do not agree to be followed according to the study protocol or have cognitive or physical inability to follow the treatment plan.
References
Publications (0)
Data not yet available
No reference posted for this study.